Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan

NCT03020095 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C

Interventions

DRUG: Ravidasvir
DRUG: Danoprevir
DRUG: Ritonavir
DRUG: Ribavirin

Sponsor

Ascletis Pharmaceuticals Co., Ltd.